1Portieje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura [ J ]. lood ,2001,97 (7) :2549-2554.
2Wang T, Zhao H, Ren H, et al. Type 1 and type 2 T-cell profiles in id- iopathic thrombocytopenic purpura [ J ]. Haematologica, 2005, 90 ( 11 ) :914-923.
3Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti - CDZOraonoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura[J ]. Blood, 2001,98 : 952 - 957.
4Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic throm- bocytopenic purpura[J]. Ann Intern Mad, 2007, 146 25 - 33.
5Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus ritux- imab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia [J].Blood, 2010, 115:2 755 - 2 762.
6Shah D, Ledbetter JA, Press OW. Signaling events involved in anti - CD20 -- induced apoptosis of malignant human B cells[J ]. Can- cer Immunol Immunother, 2000, 48 : 673 - 683.
8Yerbij FC, Fijnheer R, Voorberg J, et al. Acquired TrP: ADAMTS13 meets the immune system [ J ]. Blood Rev, 2014,28 ( 6 ) : 227 -234.
9Perez-Roddguez A, Loures E, Rodriguez-Trillo A, et al. Inherited AD- AMTS13 deficiency ( Upshaw-Schulman syndrome ) : A short review [J]. Thromb Res,2014,134(6) :1171-1175.
10Paul Knobl. Inherited and acquired thrombotic thrombocytopenic pur- pura (TTP) in adults[ J]. Semin Thromb Hemost,2014,40(4) :493- 502.
